This research used stable isotope tracing and microbiota-depleted mice to reveal that salvage NAD+ precursor supplements like nicotinamide (NAM) and nicotinamide ribose (NMR) don't actually boost NAD+, but depend on bacteria to first convert them into nicotinic acid. And that the resulting nicotinic acid is the converts to NAD+ via the Preiss Handler pathway.